BRPI0619934A2 - composição farmacêutica de liberação prolongada, processo para a preparação de uma composição, uso de uma composição, e, uso de uma composição - Google Patents

composição farmacêutica de liberação prolongada, processo para a preparação de uma composição, uso de uma composição, e, uso de uma composição Download PDF

Info

Publication number
BRPI0619934A2
BRPI0619934A2 BRPI0619934-8A BRPI0619934A BRPI0619934A2 BR PI0619934 A2 BRPI0619934 A2 BR PI0619934A2 BR PI0619934 A BRPI0619934 A BR PI0619934A BR PI0619934 A2 BRPI0619934 A2 BR PI0619934A2
Authority
BR
Brazil
Prior art keywords
composition according
composition
stearic acid
drug
grams
Prior art date
Application number
BRPI0619934-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Alan Smith
Ann Margaret Dyer
Original Assignee
Archimedes Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archimedes Dev Ltd filed Critical Archimedes Dev Ltd
Publication of BRPI0619934A2 publication Critical patent/BRPI0619934A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0619934-8A 2005-12-15 2006-12-15 composição farmacêutica de liberação prolongada, processo para a preparação de uma composição, uso de uma composição, e, uso de uma composição BRPI0619934A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0525461.0A GB0525461D0 (en) 2005-12-15 2005-12-15 Pharmaceutical compositions
GB0525461.0 2005-12-15
PCT/GB2006/004710 WO2007068948A2 (en) 2005-12-15 2006-12-15 Pharmaceutical sustained release compositions comprising in particular thyroid hormones

Publications (1)

Publication Number Publication Date
BRPI0619934A2 true BRPI0619934A2 (pt) 2011-10-25

Family

ID=35736122

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0619934-8A BRPI0619934A2 (pt) 2005-12-15 2006-12-15 composição farmacêutica de liberação prolongada, processo para a preparação de uma composição, uso de uma composição, e, uso de uma composição

Country Status (8)

Country Link
US (1) US8460702B2 (https=)
EP (1) EP1978950A2 (https=)
JP (1) JP2009519313A (https=)
BR (1) BRPI0619934A2 (https=)
CA (1) CA2634006C (https=)
GB (1) GB0525461D0 (https=)
IL (1) IL192091A (https=)
WO (1) WO2007068948A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057464A2 (en) * 2006-11-01 2008-05-15 King Pharmaceuticals Research And Development, Inc. Compositions and methods for improving the bioavailability of liothyronine
WO2013096596A1 (en) * 2011-12-20 2013-06-27 Latham Keith R Sustained drug release and improved product stability using non-covalent particle coating methods
EP3125873B1 (en) * 2014-04-04 2020-06-03 Pharmaquest International Center, LLC Disintegrating monolithic modified release tablets containing quadri-layer extended release granules
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
US10695309B2 (en) 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof
WO2020044314A1 (en) 2018-08-31 2020-03-05 Opko Ireland Global Holdings, Ltd. Vitamin d pediatric dosage forms, methods of making and using
US20220409567A1 (en) * 2021-06-23 2022-12-29 Thomas Winston Adjuvant and complementary therapies for the treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806359A (en) 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
DE69224809T2 (de) 1991-12-30 1998-07-09 Akzo Nobel Nv Thyroaktive Zusammensetzung mit kontrollierter Freigabe
GB9401892D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
EP1049459B1 (en) 1998-01-20 2009-04-22 Applied Analytical Industries, Inc. Oral liquid compositions
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications
BR9914251A (pt) * 1998-10-01 2001-06-19 Novartis Ag Formulações orais de liberação sustentada
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6288117B1 (en) * 2000-03-23 2001-09-11 North Shore-Long Island Jewish Research Institute Method for treating congestive heart failure
CN1187052C (zh) 2000-03-30 2005-02-02 布里斯托尔-迈尔斯斯奎布公司 含有司他夫定(stavudine)的持续释放微球
EP1274401B2 (en) * 2000-04-10 2014-08-13 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
WO2003075830A2 (en) * 2002-03-14 2003-09-18 Sun Pharmaceutical Industries Limited Oral controlled drug delivery system containing carbamazepine
ITMI20022394A1 (it) * 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
AU2006230557A1 (en) * 2005-03-31 2006-10-05 King Pharmaceuticals Research & Development, Inc. Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same

Also Published As

Publication number Publication date
CA2634006A1 (en) 2007-06-21
US20090130202A1 (en) 2009-05-21
JP2009519313A (ja) 2009-05-14
IL192091A0 (en) 2008-12-29
GB0525461D0 (en) 2006-01-25
WO2007068948A2 (en) 2007-06-21
EP1978950A2 (en) 2008-10-15
US8460702B2 (en) 2013-06-11
WO2007068948A3 (en) 2007-08-16
CA2634006C (en) 2013-07-30
IL192091A (en) 2012-04-30

Similar Documents

Publication Publication Date Title
EP2566462B1 (en) Immediate release formulations and dosage forms of gamma-hydroxybutyrate
CA2926082C (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
KR100882156B1 (ko) 나테글리니드 함유 제제
US20100203119A1 (en) Pharmaceutical treatment process using chitosan or derivative thereof
PT86212B (pt) Processo para a preparacao de uma formulacao galenica
JPH0251402B2 (https=)
BRPI0608853B1 (pt) composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes
JPH07558B2 (ja) モピダモール製剤
JPH0759501B2 (ja) ペレツト製剤
AU2010211980A1 (en) Dual release pharmaceutical suspension
JP2003528905A (ja) スタブジン含有持続放出性ビーズ剤
CN103889455A (zh) 稳定化乙哌立松医药组成物及含有上述组成物的缓释制剂
IL192091A (en) Sustained release pharmaceutical compositions comprising liothyronine, process for their preparation and their use in the manufacture of medicaments
KR102361246B1 (ko) 시스테아민 또는 이의 염을 포함하는 서방형 약학적 조성물
AU2004251439A1 (en) Tablet comprising fluvastatin and carmellose calcium
WO2002034268A1 (en) Sustained-release preparation containing 5-acetyl-4,6-dimethyl-2-[2-[4-(2-methoxyphenyl)piperazinyl]ethylamino]pyrimidine trihydrochloride as active ingredient
EP2808019B1 (en) Improved nitazoxanide composition and preparation method thereof
JP4842960B2 (ja) 低水溶性薬物とともに使用することによく適した圧縮固体状投与形態の製造方法およびそれにより製造された圧縮固体状投与形態
JP2006160627A (ja) 時限放出化方法
BR102018016507A2 (pt) Composição líquida de liberação prolongada de guaifenesina
CN116687961B (zh) 一种含有兰索拉唑及碳酸氢钠的干混悬剂及其制备方法
KR20040079325A (ko) 메트포르민 및 글리부라이드의 고형 경구용 제형 및 이의제조 방법
CN113164455B (zh) 难溶性药物的固体分散体
JPS6339814A (ja) トラニラストの経口用持続性製剤
JP2006160626A (ja) 徐放化方法

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2284 DE 14/10/2014.